Camrelizumab with chemoradiation before breast cancer surgery
Part of Cancer clinical trials.
This trial tests whether giving the immunotherapy drug camrelizumab along with chemotherapy and radiation before surgery can help shrink early-stage triple-negative breast cancer tumors. It aims to improve treatment outcomes for this aggressive but curable cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75 with newly diagnosed, untreated breast cancer.
- Your cancer must be 'triple-negative' — meaning it tests negative for estrogen, progesterone, and HER2.
- The cancer is early-stage and has not spread to other organs (though it may be in the lymph nodes).
- You have not had any prior cancer treatment beyond the diagnostic biopsy.
- You must not have a history of autoimmune disease, organ transplant, or HIV/hepatitis infection.
- You must be willing to use effective birth control during and for 90 days after the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding camrelizumab (an immunotherapy drug) to radiation can improve outcomes and be safe for people with early triple-negative breast cancer. It is designed for specific early-stage cases after breast surgery, using tumor and blood tests to match the cancer’s features.
This trial tests a new combination of an immunotherapy drug (camrelizumab) with chemotherapy (nab-paclitaxel) and an allergy medicine (levocetirizine) for people with triple negative breast cancer that has spread or come back. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests whether adding an immunotherapy drug (camrelizumab) to standard chemotherapy before surgery can improve outcomes for women with early-stage triple-negative breast cancer. The treatment is given before surgery to shrink tumors and may help prevent the cancer from coming back.
This Phase 2 trial tests adding camrelizumab (an immune therapy) to standard chemotherapy before surgery for people with triple-negative breast cancer that has not spread. It aims to improve how much the tumor shrinks before and around the time of surgery.
This trial studies giving camrelizumab plus apatinib and chemotherapy before surgery for triple-negative breast cancer. The goal is to shrink the tumor and improve outcomes by testing a combination of immune and targeted medicines along with chemotherapy.
This trial tests a combination of two drugs (camrelizumab and pirfenidone) with chemotherapy to see if it can help people with advanced triple-negative breast cancer. It may offer a new treatment option for those whose cancer has progressed after initial treatment.
Hear when a new TNBC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.